Michael Kragh

2.5k total citations
51 papers, 1.4k citations indexed

About

Michael Kragh is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Michael Kragh has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 23 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Molecular Biology. Recurrent topics in Michael Kragh's work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Lung Cancer Treatments and Mutations (15 papers). Michael Kragh is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Lung Cancer Treatments and Mutations (15 papers). Michael Kragh collaborates with scholars based in United States, Denmark and Spain. Michael Kragh's co-authors include Mikkel W. Pedersen, Helle J. Jacobsen, Ivan D. Horak, Klaus Koefoed, Johan Lantto, Paul E.G. Kristjansen, John S. Haurum, Adam Hey, Thomas T. Poulsen and Charles Pyke and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and JNCI Journal of the National Cancer Institute.

In The Last Decade

Michael Kragh

50 papers receiving 1.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Kragh	753	509	488	318	259	51	1.4k
Paul Balderes	397 0.5×	736 1.4×	381 0.8×	173 0.5×	121 0.5×	32	1.2k
Veronica Steri	827 1.1×	796 1.6×	158 0.3×	705 2.2×	205 0.8×	34	1.8k
Amandine Alard	851 1.1×	576 1.1×	162 0.3×	724 2.3×	315 1.2×	13	1.6k
Jean-Michel Vernes	552 0.7×	613 1.2×	365 0.7×	462 1.5×	89 0.3×	15	1.3k
Saraswathy Seetharam	419 0.6×	969 1.9×	206 0.4×	362 1.1×	216 0.8×	25	1.6k
Markus Münz	1.0k 1.4×	1.0k 2.0×	269 0.6×	330 1.0×	131 0.5×	18	1.9k
C. Kieu	560 0.7×	700 1.4×	131 0.3×	185 0.6×	135 0.5×	10	1.2k
Mingqian Feng	360 0.5×	598 1.2×	295 0.6×	371 1.2×	136 0.5×	49	1.3k
Khaled Tolba	493 0.7×	632 1.2×	214 0.4×	464 1.5×	313 1.2×	50	1.5k
Camilla L. Christensen	600 0.8×	795 1.6×	197 0.4×	158 0.5×	202 0.8×	34	1.4k

Countries citing papers authored by Michael Kragh

Since Specialization

Citations

This map shows the geographic impact of Michael Kragh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kragh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kragh more than expected).

Fields of papers citing papers by Michael Kragh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kragh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kragh. The network helps show where Michael Kragh may publish in the future.

Co-authorship network of co-authors of Michael Kragh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kragh. A scholar is included among the top collaborators of Michael Kragh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kragh. Michael Kragh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reddy, T. P., Wei Qian, Wen Chen, et al.. (2020). Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Research. 22(1). 48–48. 13 indexed citations

Jones, Sylwia, Peter King, Costin N. Antonescu, et al.. (2020). Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. Scientific Reports. 10(1). 663–663. 24 indexed citations

Gjetting, Torben, Monika Gad, Camilla Fröhlich, et al.. (2019). Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. mAbs. 11(4). 666–680. 25 indexed citations

Sánchez-Martín, Francisco Javier, Oriol Arpí, Laura Visa, et al.. (2019). HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Molecular Cancer Therapeutics. 18(11). 2135–2145. 42 indexed citations

Schoemaker, Rik C., Clara Montagut, Scott Kopetz, et al.. (2019). Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. Journal of Pharmacokinetics and Pharmacodynamics. 47(1). 5–18. 3 indexed citations

Calvert, Valerie, Shruti Rao, Simina M. Boca, et al.. (2018). Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015. Molecular Cancer Therapeutics. 17(6). 1259–1270. 9 indexed citations

Poulsen, Thomas T., Michael M. Grandal, Klaus Koefoed, et al.. (2017). Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors. Clinical Cancer Research. 23(19). 5923–5935. 42 indexed citations

Grandal, Michael M., Thomas T. Poulsen, Klaus Koefoed, et al.. (2017). Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. Molecular Cancer Therapeutics. 16(12). 2780–2791. 23 indexed citations

Schwarz, Luis J., Katherine E. Hutchinson, Brent N. Rexer, et al.. (2017). An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. JNCI Journal of the National Cancer Institute. 109(11). 35 indexed citations

10.

Bardelli, Alberto, Thomas T. Poulsen, Rodrigo Dienstmann, et al.. (2017). Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004. Annals of Oncology. 28. v34–v34. 1 indexed citations

11.

Tabernero, Josep, Fortunato Ciardiello, Clara Montagut, et al.. (2017). Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S). Annals of Oncology. 28. v160–v160. 2 indexed citations

12.

Lindsted, Trine, Camilla Fröhlich, Jesper V. Olsen, et al.. (2016). Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures. Molecular Cancer Therapeutics. 15(7). 1614–1626. 15 indexed citations

13.

Iida, Mari, Harsh Bahrar, Toni M. Brand, et al.. (2016). Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Molecular Cancer Therapeutics. 15(9). 2175–2186. 33 indexed citations

14.

Jacobsen, Helle J., Thomas T. Poulsen, Anna Dahlman, et al.. (2015). Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clinical Cancer Research. 21(18). 4110–4122. 71 indexed citations

15.

Dienstmann, Rodrigo, Amita Patnaik, Rocio García‐Carbonero, et al.. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. 5(6). 598–609. 58 indexed citations

16.

Pedersen, Mikkel W., Helle J. Jacobsen, Klaus Koefoed, et al.. (2015). Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance. Molecular Cancer Therapeutics. 14(3). 669–680. 42 indexed citations

17.

Francis, David M., Shyhmin Huang, Eric A. Armstrong, et al.. (2015). Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models. Clinical Cancer Research. 22(3). 633–643. 22 indexed citations

18.

Huang, Shyhmin, Chimera R. Peet, Jarob Saker, et al.. (2013). Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers. Molecular Cancer Therapeutics. 12(12). 2772–2781. 12 indexed citations

19.

Pedersen, Mikkel W., Helle J. Jacobsen, Klaus Koefoed, et al.. (2010). Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy. Cancer Research. 70(2). 588–597. 174 indexed citations

20.

Søndergaard, Henrik, Klaus Stensgaard Frederiksen, Peter Thygesen, et al.. (2007). Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunology Immunotherapy. 56(9). 1417–1428. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact